The first heart transplant and first lung transplant were performed by Dr Norman Shumway at Stanford University Hospital in 1968 and Dr Joel Cooper with his Toronto Lung Transplantation (LT) Group in 1983, respectively. 1, 2 Advances in surgical techniques, discovery of immunosuppressive drugs such as cyclosporin, and better perioperative care including anesthesia and intensive care have contributed to transplant recipients' improved survival over years. Several ground-breaking developments, including prehabilitation of transplant candidates, perioperative use of extracorporeal membrane oxygenation (ECMO), ex vivo lung perfusion, and newer regional analgesic techniques, have improved outcomes after LT and heart transplantation in recent years. This themed issue of Seminars in Cardiothoracic and Vascular Anesthesia (SCVA) is dedicated to describing the advances in the perioperative care of thoracic organ transplantation recipients.
While left ventricular assist device (LVAD) therapy improves organ perfusion and survival in end-stage heart failure patients, the complexity of the orthotopic heart transplantation (OHT) surgical procedure in patients with LVAD may increase perioperative organ injury and complications because of exaggerated systemic inflammatory responses. 3 Patients with LVADs are also prone to developing complications like thrombosis and device malfunction. 4, 5 The effect of prior LVAD therapy on outcomes after OHT is highly debated. 6, 7 Pal and colleagues addressed this complex issue in their excellent review, "Heart Transplantation after Ventricular Assist Device Therapy: Benefits, Risks and Outcomes." 8 The authors concluded that while the optimal timing of OHT after LVAD is not known, performing OHT too early before LVAD improved end-organ function, and performing OHT too late after development of an LVADrelated complication will likely adversely affect survival. Another important issue affecting the outcomes of patients receiving OHT is early graft failure (EGF), which has been reported to occur up to 30% of recipients. 9 The incidence of EGF has not changed over years. 10 Identification of immunological mechanisms contributing to EGF such as antibody sensitization may lead to the development of preventive measures and therapies to improve survival and quality of life for OHT recipients. Subramani and colleagues in their review "Early Graft Dysfunction Following Heart Transplant: Prevention And Management" analyzed the incidence, etiopathogenesis, risk factors, preventive measures, and therapies of EGF occurring within 24 hours of OHT to give updates on this important topic in this special issue. 11 Changes in allocation policies bring patients with very advanced and unstable cardiopulmonary disease to the operating room. Similar to OHT recipients with prior LVAD support, LT recipients are bridged to transplantation with ECMO more frequently as transplant teams nowadays recognize the perioperative utility of this improved technology. ECMO is also utilized in the operating room in preference to cardiopulmonary bypass to facilitate lung implantation, and early retrospective studies seem to favor ECMO for reduced blood transfusion, improved postoperative outcomes, and possibly improved survival. 12 Prospective clinical trials are required to match preoperative patient characteristics and condition of the recipient at the time of transplantation. Hayanga and colleagues describe the utility of ECMO in perioperative management in the review article "Role of Mechanical Circulatory Support in Perioperative Management of Thoracic Organ Transplantation." The authors very well summarized current evidence supporting the use of ECMO in LT. 13 Donor organ availability is the major limitation to LT, and several strategies have been utilized to increase the donor pool such as donation after cardiac death, use of marginal donor organs, and ex vivo lung perfusion. Ex vivo lung perfusion is exciting, as it presents an opportunity to evaluate and recondition marginal lungs so that some of them can be potentially utilized for the countless number of recipients on the waiting list. 14 Chan and colleagues in their review described the history, equipment, and techniques used in ex vivo lung perfusion. 15 They also presented clinical studies showing the benefits of this method and provided future directions. While we attempt to improve the prospects of organ utilization by various methods, understanding the pathogenesis of primary graft dysfunction (PGD) is vital for preservation of organ function after implantation. The incidence and mortality of PGD are not insignificant. Wilkey and Abrams explored the donor factors, recipient variables, preservation methods, and intraoperative factors that can affect the development of PGD in their article "Mitigation of Primary Graft Dysfunction in Lung Transplantation: Current Understanding and Hopes for the Future." 16 They also described preventive strategies, management options, and future directions related to PGD.
Perioperative management, including anesthesia induction, hemodynamic monitoring, fluid and blood transfusion, pulmonary vasodilator therapy, ventilation management, and postoperative analgesia, can all without doubt influence patient outcomes after LT. [17] [18] [19] [20] In this issue of SCVA, thoracic transplant anesthesiology experts reviewed some of those important perioperative management strategies affecting LT outcomes. Blood and blood product transfusions, including large-volume red cell transfusion and platelet transfusion in the perioperative period, are implicated as factors contributing to PGD and immunologically mediated chronic allograft dysfunction. [21] [22] [23] Establishing causality is very difficult, and debate continues regarding whether pretransplant patient conditions lead to transfusion or transfusion per se contribute to lung injury. Pena and colleagues in this issue thoroughly reviewed the literature behind blood management and outcomes in LT recipients. In their review titled "Perioperative Management of Bleeding and Transfusion for Lung Transplantation," they also highlighted the role of point-of-care coagulation, goal-directed transfusion, factor concentrates, and other blood conservation options like antifibrinolytics in LT recipients. 24 Inhaled pulmonary vasodilator therapy is commonly used for various indications during and after thoracic organ transplantation. 25 Krebs and Morita did an excellent review of the scientific rationale and clinical evidence supporting the continued use of inhaled pulmonary vasodilators. 26 The authors concluded that inhaled pulmonary vasodilators are very useful in short-term therapy for acute right heart failure and pulmonary hypertensive crisis. No definite evidence exists to support the utility of inhaled nitric oxide in the prevention or treatment of PGD in humans. Despite the long history of clinical use of inhaled pulmonary vasodilators, optimal dosing, timing, duration, and long-term benefits have not been explored in large clinical trials, and the cost-effectiveness of their routine use in thoracic transplant recipients is questionable. Patient-Reported Outcomes Measurement Information System (PROMIS) can be used to track long-term outcomes in transplantation recipients. This issue includes an original article from Klinger and colleagues on the incidence and severity of chronic pain after LT using a PROMIS survey. 27 Although chronic pain was reported in almost half of the survey respondents, severe pain was rare. These surveys are only exploratory because of the lower response rate and associated bias. Acute pain management after LT may play a significant role in the prevention of chronic pain, and prospective clinical trials with larger sample sizes should be conducted to evaluate pain-related outcomes after LT.
Combined thoracic and abdominal transplantation procedures are rare but require special knowledge on the perioperative implications of both transplantable organs and the complexity of the surgical procedure. These procedures and anesthesia implications are rarely described in anesthesia literature. Yager and colleagues in this issue discuss preoperative considerations, ethical dilemmas, and intraoperative management and postoperative care of patients undergoing combined heart-kidney, heart-liver and lung-liver transplants. 28 The authors did an excellent job of reviewing the topic, which has recommendations mostly based on specialized centers' experiences. They recommend the involvement of anesthesiologists from the beginning of the selection process, a multidisciplinary, team-based approach, and postoperative care in a cardiothoracic surgical intensive care unit. They also mentioned that survival after combined transplantation is quite comparable with that after individual organ transplantation, and combined organ transplants could confer protection against rejection.
One of the missions of the Society for Advancement of Transplant Anesthesia (SATA) is to promote education and establish guidelines for proper training in the field of thoracic and abdominal transplant anesthesiology. 29 This will ensure that transplant patients are cared for by competent anesthesiologists trained specifically in this particular area. Anesthesia and perioperative care for LT patients are very complex and require special skillsets in intraoperative management and echocardiography. Cardiac anesthesiologists provide anesthesia for LT in most institutions, but fellowship training in cardiac anesthesiology alone may not always ensure adequate exposure to LT procedures. Many accredited Adult Cardiothoracic Anesthesiology (ACTA) Fellowship Training programs may not have integrated LT programs. There are no details in the Accreditation Council for Graduate Medical Education (ACGME) document on ACTA fellowships regarding the milestones required for competency in LT anesthesiology. Wilkey and colleagues assembled a group of thoracic transplant anesthesiology experts and wrote milestones for training in LT anesthesiology based on 6 core competencies created by the ACGME. 30 We believe that this will initiate discussion among cardiothoracic anesthesiologists, transplantation anesthesiologists, and surgeons regarding super-specialty training and requirements for such training in thoracic transplantation anesthesiology.
In this special issue of our journal, we compiled a group of articles from experts affiliated with SATA that address recent developments, key questions, and future directions in the field of heart and LT. As we recognize rapidly changing practices in donor allocation, preoperative preparation and optimization of recipients, organ preservation, and intraoperative management and postoperative care of transplant recipients, we as thoracic transplantation anesthesiology specialists believe in being better prepared to match the advances in other related fields of the thoracic transplantation world and meet the needs for excellent perioperative patient care.
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